Infection-associated urticaria: Persistence, recurrence, and chronicity :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Long-term outcomes of infection-associated urticaria following viral infections

Infection-associated urticaria Infection-associated urticaria
Infection-associated urticaria Infection-associated urticaria

Urticaria presents as short-lived wheals, angioedema, or both. It is termed acute urticaria (AU) when it lasts under 6 weeks and chronic urticaria when it lasts 6 weeks or longer.

See All

Key take away

While infection-associated urticaria is predominantly self-limiting and resolves within weeks, up to 9.5% of cases persist beyond 6 months, with overall recurrence and chronicity rates ranging from 7% to 30%. Delayed-onset cases following SARS-CoV-2 infection carry a distinct risk for progression to chronic spontaneous urticaria.

Background

Urticaria presents as short-lived wheals, angioedema, or both. It is termed acute urticaria (AU) when it lasts under 6 weeks and chronic urticaria when it lasts 6 weeks or longer. AU is often set off by infections, drugs, or foods, whereas chronic urticaria, especially chronic spontaneous urticaria (CSU), is usually idiopathic or immune-driven.

Viruses are a leading reported cause of AU, particularly in children, with respiratory and gastrointestinal infections implicated most often. The rash typically coincides with or follows the infection and fades within days to weeks, but some patients appear to have longer courses: ongoing symptoms, relapse after a clear spell, or progression to chronic urticaria. The long-term picture remains poorly characterized, since studies differ in design, populations, definitions, and follow-up, and many pool several triggers. Reports of delayed or prolonged urticaria after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have heightened interest.

Although previous research identified infections as triggers in 45.2% of pediatric AU cases and reported a link with prolonged symptom duration, it did not investigate subsequent clinical outcomes through long-term follow-up. Similarly, existing reviews have largely concentrated on acute clinical manifestations, diagnostic approaches, and individual infectious agents, particularly SARS-CoV-2, rather than the long-term course of infection-associated urticaria. Consequently, the long-term outcomes in both pediatric and adult populations remain insufficiently understood. To the authors' knowledge, no previous systematic review has specifically synthesized the evidence addressing this question.

Method

(a) Study design

This systematic review followed the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

(b) Literature search

PubMed, Embase, CINAHL, Scopus, and Web of Science were searched from inception to 17 March 2026, without search-stage limits (language was checked at screening) and without grey literature. The search strings combined Medical Subject Headings (MeSH terms), database-indexed vocabulary, and free-text keywords targeting infection-associated urticaria, viral triggers, and long-term prognosis (persistence, chronicity, and recurrence).

Reference lists and citations of included studies and relevant reviews were also checked. After EndNote de-duplication, two reviewers independently screened titles and abstracts in Covidence, and full texts were assessed against the criteria; disagreements went to discussion or a third reviewer.

(c) Inclusion criteria

  • Children or adults with urticaria linked to, or following, viral infection and reporting persistence, chronicity, or recurrence
  • Viral infection as a possible or main trigger, including mixed-etiology AU cohorts in which infection-associated urticaria was clearly described (interpreted cautiously)
  • Observational designs, including larger case series with long-term outcomes
  • Peer-reviewed English articles with Population, Exposure, Comparator, Outcomes, and Study design (PICOS) framework

(d) Exclusion criteria

  • Case reports and small case series (<5 participants)
  • Reviews, editorials, commentaries, abstracts without full text, preprints, and other non-peer-reviewed reports
  • No long-term persistence, chronicity, or recurrence data after viral infection, including AU-only studies without follow-up
  • COVID-19-related case reports and small series of new-onset CSU after SARS-CoV-2 infection, too small to meet the larger-study requirement

(e) Data extraction

Two reviewers independently extracted author, year, country, design, sample size, population, pathogen, infection diagnosis, urticaria type, symptom duration, follow-up, and outcomes on a standard form, resolving disagreements by consensus or a third reviewer; unclear data were interpreted from study descriptions and cross-checked.

(f) Study outcomes

Long-term outcomes meant anything beyond the acute phase, using established clinical and guideline definitions:

  • Persistence: Symptoms continuing past the acute phase of the suspected or reported trigger
  • AU: Wheals, angioedema, or both lasting <6 weeks
  • Chronic urticaria: Symptoms lasting ≥6 weeks
  • CSU: Wheals, angioedema, or both without a specific identifiable external trigger
  • Recurrence: Urticaria returning after a symptom-free interval

Study-specific definitions were retained and mapped to these categories, and mixed-etiology results were read against reported or dominant triggers.

(g) Risk of bias and quality assessment

Two reviewers independently applied the Newcastle–Ottawa Scale (NOS), which scores participant selection, group comparability, and outcome assessment; totals of 7–9 indicated low risk of bias, 4–6 moderate, and 0–3 high.

(h) Data synthesis

Heterogeneity was judged qualitatively, and because pooling would likely mislead, no meta-analysis was done. Results were summarized narratively by age group (children vs. adults) and virus where possible, as evidence on infection-associated urticaria rather than confirmed post-viral urticaria.

Result

(a) Study selection and characteristics

  • Five studies involving 596 volunteers were included: three prospective cohort studies, one retrospective case–control study, and one prospective observational study.
  • Studies were executed across Europe, Asia, and the Middle East, with sample sizes ranging from 50 to 314 volunteers.
  • Most studies involved pediatric populations, particularly infants and preschool-aged children. One study primarily investigated adults following SARS-CoV-2 infection.
  • The review identified 6,135 records. After eliminating 3,049 duplicates, 3,086 records were screened, 91 full-text articles were assessed, and five studies were incorporated (Figure 1).

b) Clinical presentation and infectious triggers

Urticaria generally developed during the acute phase of infection, occurring within days before or after infection-related symptoms. The predominant presentation was pruritic wheals, with or without angioedema.

  • Aoki et al.: Most cases were mild and self-limiting, with symptoms resolving within 2 weeks.
  • Cetinkaya et al.: Angioedema occurred in approximately 28% of patients, while anaphylaxis was reported in approximately 3.6%. Upper respiratory tract infections were common triggers, and greater disease severity was associated with longer symptom duration.
  • Kara et al.: Acute urticaria occurred concurrently with COVID-19 and generally resolved within approximately 1 week. Delayed-onset CSU presented with a more prolonged course.
  • Mortureux et al.: All patients in this hospitalized cohort had generalized urticaria, frequently involving annular or geographic lesions. Angioedema occurred in approximately 60%, fever in 50%, respiratory symptoms in 60%, and arthralgia in 30%. Haemorrhagic lesions were more frequent in infection-associated cases.
  • Talarico et al.: Disease severity was classified as mild in 40.4%, moderate in 44.5%, and severe in 14.9% of patients. Most cases were self-limiting.

(c) Persistence and progression to chronic urticaria

Most infection-associated urticaria cases resolved within weeks to months. However, prolonged symptoms were documented in a subset of patients.

  • Aoki et al.: Approximately 86% of patients experienced resolution within 2 weeks and 96% within 3 months. Nevertheless, 2/50 patients (about 4%) experienced persistent symptoms beyond 1 year.
  • Talarico et al.: Persistence was reported in nearly 30/314 patients (9.5%) at 6 months. These findings represented the entire mixed-etiology cohort and were not separately attributed to viral infections.
  • Kara et al.: Following SARS-CoV-2 infection, 7/92 patients developed CSU, with an approximate mean symptom duration of 7.5 months. In contrast, AU resolved within approximately 1 week.

(d) Recurrence and chronicity

Infection-associated urticaria recurred or progressed to chronic disease in a subset of patients, highlighting variability in its long-term clinical course (Table 1).

Importantly, recurrence and chronicity estimates from several studies were derived from mixed-etiology cohorts, limiting their direct attribution to viral infections.

(e) Factors associated with prolonged disease

  • Delayed-onset urticaria, particularly more than 2 weeks after SARS-CoV-2 infection, was associated with an increased likelihood of progression to CSU.
  • Greater initial disease severity, angioedema, and infection-related triggers were also associated with prolonged or recurrent symptoms.
  • Eosinopenia was associated with CSU in the SARS-CoV-2 cohort.

(f) Risk of bias

All five studies illustrated moderate risk of bias.

Discussion

This systematic review offers a critical synthesis of the long-term clinical trajectory of infection-associated urticaria, challenging the traditional view that post-viral cutaneous eruptions are strictly self-limiting. While the vast majority of subjects experience rapid symptom resolution within weeks, the identification of a persistence rate up to 9.5% beyond 6 months—alongside overall recurrence and chronicity rates between 7% and 30%—underscores that a clinically meaningful subgroup develops prolonged dermatological disease. These findings emphasize the need to re-evaluate clinical follow-up timelines for those presenting with post-viral urticarial flares.

A particularly noteworthy finding is the distinct clinical phenotype linked with SARS-CoV-2 infection, where delayed-onset urticaria was consistently linked to an increased risk of progression towards CSU. This observed pattern points toward potential post-viral immunological mechanisms, such as sustained immune dysregulation, persistent low-grade inflammation, or cross-reactive autoimmune responses triggered by viral antigens. Recognizing these delayed-onset risk patterns is fundamental for clinicians evaluating post-infectious cutaneous sequelae in both pediatric and adult populations.

Limitations

  • Few studies, with marked differences in populations, triggers, outcome definitions, and follow-up, preclude firm or generalizable conclusions and reveal an evidence gap.
  • Mixed-etiology cohorts without trigger stratification limit causal inference, so several estimates are indirect evidence for infection-associated urticaria rather than pathogen-specific risk.
  • Evidence on delayed onset and progression to chronicity rests mainly on SARS-CoV-2 cohorts, which may not apply to other viruses.
  • Studies were mostly observational at moderate risk of bias, with little confounder adjustment and no standardized outcome definitions.
  • No formal Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment was made, owing to heterogeneous designs and outcome measures.

Clinical take-away

Infection-associated urticaria is generally self-limiting. However, clinicians must recognize that a subset of patients may develop persistent, recurrent, or chronic symptoms. Delayed-onset urticaria, particularly following SARS-CoV-2 infection, may signal a greater likelihood of progression to CSU and warrants consideration of closer follow-up.

Although reassurance is appropriate for most pediatric patients, recurrence and chronicity must be discussed with caregivers. Careful differentiation between infection-induced and drug-induced urticaria, alongside individualized follow-up, may help improve clinical assessment and patient counselling.

Source:

Frontiers in Allergy

Article:

Persistence, chronicity, and recurrence of infection-associated urticaria following viral infections in children and adults: a systematic review

Authors:

Saad Alhumaid et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: